Get the Stockscreener App
5.62
2.18%
0.12
After Hours:
5.66
0.04
+0.71%
Karyopharm Therapeutics Inc stock is traded at $5.62, with a volume of 171.62K.
It is up +2.18% in the last 24 hours and down -12.87% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$5.50
Open:
$6.01
24h Volume:
171.62K
Relative Volume:
0.77
Market Cap:
$48.73M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.5102
EPS:
-11.016
Net Cash Flow:
$-102.89M
1W Performance:
-8.77%
1M Performance:
-12.87%
6M Performance:
+31.00%
1Y Performance:
-56.49%
1-Day Range:
$5.60
$6.15
1-Week Range:
$4.5101
$6.2881
52-Week Range:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
5.62 | 47.69M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Building trade automation scripts for Karyopharm Therapeutics Inc.July 2025 Update & High Accuracy Swing Entry Alerts - newser.com
KPTI Receives Upgrade to 'Buy' from HC Wainwright & Co. | KPTI Stock News - GuruFocus
Karyopharm Therapeutics stock rating upgraded to Buy by H.C. Wainwright - Investing.com Canada
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
HC Wainwright Upgrades Karyopharm Therapeutics to Buy From Neutral, $15 Price Target - MarketScreener
Sector ETF performance correlation with Karyopharm Therapeutics Inc.Weekly Trend Report & AI Based Trade Execution Alerts - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock a top hedge fund pickMarket Growth Summary & Precise Swing Trade Alerts - newser.com
What to expect from Karyopharm Therapeutics Inc. in the next 30 days2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - newser.com
News impact scoring models applied to Karyopharm Therapeutics Inc.2025 Risk Factors & Long-Term Safe Investment Plans - newser.com
Using R and stats models for Karyopharm Therapeutics Inc. forecastingPortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
Heatmap analysis for Karyopharm Therapeutics Inc. and competitors2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Will Karyopharm Therapeutics Inc. continue its uptrend2025 Geopolitical Influence & Advanced Technical Analysis Signals - newser.com
Can a trend reversal in Karyopharm Therapeutics Inc. lead to recoveryPortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Karyopharm Secures $100M Financing for Clinical Trials - MSN
KPTI: Piper Sandler Reiterates Overweight Rating, Lowers Price T - GuruFocus
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
KPTI Strengthens Financial Position with $100M Capital Strategy - GuruFocus
Karyopharm Therapeutics stock price target lowered to $6 at Leerink Partners - Investing.com Canada
Karyopharm Raises $100M to Extend Cash Runway Through 2026Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga
Karyopharm Announces Strategic Financing Transactions to Support Growth - citybiz
Karyopharm announces strategic financing - The Pharma Letter
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Three Months Ended September 30, 2025 - MarketScreener
Karyopharm secures $100 million in financing to extend cash runway By Investing.com - Investing.com Australia
Karyopharm stock falls after announcing $100 million financing deal By Investing.com - Investing.com Canada
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - WV News
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50-Day Moving AverageHere's Why - MarketBeat
Karyopharm Therapeutics Inc. announced that it expects to receive $23.748952 million in funding - MarketScreener
Myelofibrosis Market Overview: Epidemiology, Therapies, - openPR.com
Is Karyopharm Therapeutics Inc. stock oversold or undervaluedEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Will Karyopharm Therapeutics Inc. rebound enough to break evenGlobal Markets & AI Driven Price Predictions - newser.com
Measuring Karyopharm Therapeutics Inc.’s beta against major indicesQuarterly Trade Report & AI Driven Stock Movement Reports - newser.com
Selinexor Study Withdrawal: Implications for Karyopharm Therapeutics - TipRanks
Using data filters to optimize entry into Karyopharm Therapeutics Inc. - newser.com
How Karyopharm Therapeutics Inc. (25K0) stock trades pre earningsJuly 2025 Institutional & Verified Trade Idea Suggestions - newser.com
Multi asset correlation models including Karyopharm Therapeutics Inc.July 2025 Closing Moves & Safe Entry Zone Tips - newser.com
Backtesting results for Karyopharm Therapeutics Inc. trading strategiesWeekly Profit Recap & Daily Volume Surge Signals - newser.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Karyopharm Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener
Cancer Therapy Pioneer Karyopharm Awards Strategic Inducement Grant Under 2022 Stock Incentive Plan - Stock Titan
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paulson Richard A. | President and CEO |
Sep 15 '25 |
Sale |
6.43 |
1,257 |
8,083 |
84,046 |
| Mano Michael | SVP, General Counsel&Secretary |
Sep 15 '25 |
Sale |
6.43 |
234 |
1,505 |
21,425 |
| Poulton Stuart | EVP, Chief Development Officer |
Sep 15 '25 |
Sale |
6.43 |
401 |
2,578 |
27,710 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Sep 15 '25 |
Sale |
6.43 |
408 |
2,623 |
29,390 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Sep 15 '25 |
Sale |
6.43 |
325 |
2,090 |
35,856 |
| Abate Kristin | Chief Accounting Officer |
Sep 15 '25 |
Sale |
6.43 |
23 |
148 |
10,408 |
| Abate Kristin | Chief Accounting Officer |
Sep 03 '25 |
Sale |
6.78 |
12 |
81 |
9,463 |
| Poulton Stuart | EVP, Chief Development Officer |
Jul 29 '25 |
Sale |
4.37 |
191 |
835 |
27,223 |
| Abate Kristin | Chief Accounting Officer |
Jul 22 '25 |
Sale |
4.00 |
238 |
952 |
9,475 |
| Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):